Investigational Studies

Shares of Cannabis Sativa Inc (OTCMKTS:CBDS) exploded up the charts on the back of positive news from GW Pharmaceuticals plc (NASDAQ:GWPH). GWPH announced positive results in a Phase 3 clinical trial assessing Orphan Drug- and Fast Track-tagged Epidiolex (cannabidiol) for the treatment of Dravet syndrome, a rare and catastrophic form of childhood epilepsy for which there are no […]

by

Over the past week, a few biotech companies made impressive runs. These moves were the result of clinical trial results, U.S. Food and Drug Administration (FDA) decisions and more. The companies 24/7 Wall St. has picked stood out from the rest with positive news guiding them last week. We have included information about each company, […]

by

The FDA designates Zynerba Pharmaceuticals’ (ZYNE +2%) ZYN002 cannabidiol gel an Orphan Drug for the treatment of Fragile X syndrome, a genetic disorder characterized by learning disabilities and cognitive impairment. ZYN002 is designed to deliver a controlled dose of cannabidiol transdermally via a permeation-enhanced gel formulation. A Phase 2 study should commence by year end. […]

by